CD274 and cancer: The discovery of PD-1 as a receptor capable of conveying negative signals to T cells (12, 13) and, soon after, the therapeutic implications of the programmed death-ligand 1 (PD-L1)/PD-1 immune checkpoint blockade brought great excitement to the field of cancer immunotherapy (12, 14).